Research
Hormonal
Tirzepatide resulted in greater hemoglobin A1c reduction from baseline compared to placebo and active comparators, with absolute reductions up to 3.02%.
Tirzepatide may be a more effective option for lowering blood sugar in patients with type 2 diabetes.
StrongSupportsmedium confidence
Hemoglobin A1c reduction from baseline was greater with tirzepatide across all studies with absolute reductions up to 3.02%.
Why this rating
Based on the results of seven phase 3 randomized trials.
Source
Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice
Courtney L. Bradley et al. · Annals of Pharmacotherapy · 2022
reviewCited 13×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →